Nyxoah S.A. (NASDAQ:NYXH) Sees Significant Drop in Short Interest

Nyxoah S.A. (NASDAQ:NYXH) was the target of a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 58,800 shares, a decline of 17.4% from the October 15th total of 71,200 shares. Based on an average daily volume of 63,200 shares, the short-interest ratio is currently 0.9 days. Approximately 0.4% of the company’s stock are sold short.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $16.00 target price on shares of Nyxoah in a report on Tuesday, November 5th. HC Wainwright dropped their price objective on Nyxoah from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Friday, October 11th. Finally, Oppenheimer decreased their target price on Nyxoah from $15.00 to $13.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $17.00.

Institutional Trading of Nyxoah

A number of large investors have recently made changes to their positions in NYXH. Iron Triangle Partners LP acquired a new position in shares of Nyxoah in the first quarter valued at approximately $3,413,000. CVI Holdings LLC purchased a new position in Nyxoah during the 2nd quarter worth $1,292,000. Ikarian Capital LLC purchased a new position in Nyxoah during the first quarter worth about $684,000. Finally, Kovack Advisors Inc. acquired a new stake in Nyxoah in the third quarter valued at about $96,000.

Nyxoah Stock Performance

NASDAQ NYXH traded down $0.21 during trading hours on Friday, hitting $8.22. The company had a trading volume of 18,951 shares, compared to its average volume of 49,495. The business has a 50 day moving average of $9.05 and a 200-day moving average of $8.74. The company has a debt-to-equity ratio of 0.21, a quick ratio of 4.95 and a current ratio of 5.28. Nyxoah has a 1-year low of $4.00 and a 1-year high of $20.00. The company has a market cap of $205.01 million, a PE ratio of -4.40 and a beta of 1.45.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.